The ART of HIV and STI Prevention: Update From the 2025 Conference on Retroviruses and Opportunistic Infections (CROI)

Assessment of Needs

This webinar will discuss current and new data around prevention of HIV and prevention of sexually transmitted infections, including new data presented at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI).

Learning Objectives

On completion of this activity, learners will be able to:

• Describe the current approaches for HIV prevention
• Describe new data presented at CROI 2025, and how they affect HIV prevention strategies in the clinic
• Summarize data on doxycycline for prevention of sexually transmitted infections
• List novel prevention approaches under evaluation

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on Tuesday, April 15, 2025, 10:30 AM (PT).

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities. 

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Presenter

Dr Buchbinder reported institutional grants/grants pending to their institution from Gilead Sciences, Inc., GlaxoSmithKline, Merck, and ViiV Healthcare;  noncash provision of medicines, equipment, or administrative support from Gilead Sciences, Inc. (Updated May 15, 2024)

Moderator

Dr Liu reported institutional grants/grants pending to their institution from Gilead Sciences, Inc., GlaxoSmithKline, Merck, and ViiV Healthcare;  noncash provision of medicines, equipment, or administrative support from Gilead Sciences, Inc. (Updated May 15, 2024)

Planner/Reviewer

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.